Ionis Plummets 19% After Blockbuster Heart Trial Fails — Biotech Disaster or Buying Opportunity?

Ionis Pharmaceuticals just suffered a brutal gut-punch, with its stock plummeting nearly 19% after a highly anticipated Phase 3 heart drug trial completely missed its primary goals. The sudden failure wiped out all the momentum from a major FDA approval just weeks prior. But the real twist? Corporate insiders quietly dumped over $25 million in shares leading up to the announcement, leaving retail investors holding the bag.

In this episode of Implied, we break down the clinical disaster, unpack the suspicious insider selling, and analyze the company's explosive 87% revenue growth that's still humming behind the scenes. Is this crash a warning to stay far away, or is the market overreacting to a single setback, leaving a heavily diversified biotech giant deeply undervalued? Tune in to find out if this is a dangerous trap or a rare, high-upside entry point.